Composite Mosapride Rabeprazole Tablet Core-Shell Structure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of composite preparations that effectively combine mosapride and rabeprazole without interfering with their dissolution patterns or causing side effects, which are essential for treating digestive issues like diabetic gastropathy and peptic ulcers.
Innovation Solution
A composite preparation is developed with a core tablet structure containing rabeprazole surrounded by a mosapride outer layer, or in the form of enteric-coated tablets and pellets, to ensure rapid and controlled drug release, improving bioavailability and stability while reducing excipient amounts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If a composite preparation of mosapride and rabeprazole is developed, then drug compliance and economic benefits are improved, but dissolution pattern changes and side effects may occur due to drug interaction
Solution Approach 1:
The patent divides the composite preparation into distinct spatial segments: an inner core containing rabeprazole and an outer layer containing mosapride. This segmentation physically separates the two drugs, preventing direct interaction while maintaining their individual dissolution patterns and efficacy.
Solution Approach 2:
The patent employs a nested structure where the rabeprazole-containing inner core is enclosed within the mosapride-containing outer layer. This nesting arrangement allows both drugs to be delivered in a single preparation while maintaining separate dissolution environments, thus preserving reliability while improving compliance.
2Reliability
If a composite preparation combines multiple drugs, then therapeutic efficacy is improved, but the amount of excipient increases
Solution Approach 1:
The patent merges two separate drug preparations into a single composite tablet structure, combining rabeprazole and mosapride in one dosage form. This merging reduces the total excipient amount compared to providing separate tablets, as the excipients are shared across the unified structure while maintaining both therapeutic efficacies.
3Productivity
If a core tablet structure with rabeprazole inner core and mosapride outer layer is used, then drug release control is improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies preliminary action by pre-forming the rabeprazole inner core and mosapride outer layer as separate components before assembling them into the final composite tablet. This allows each layer to be optimized for its specific drug release characteristics while simplifying the overall manufacturing process through modular assembly.
Data Source
AI summary
The present invention relates to a composite preparation with various dosage forms comprising mosapride and rabeprazole.The composite preparation prepared according to the present invention allows rapid release of a drug without deteriorating its release by an interaction between mosapride and rabeprazole, thus exhibiting an improved drug release rate and bioavailability, while having excellent product stability and being capable of significantly lowering the amount of the excipient. Accordingly, the composite preparation of the present invention can improve patients' drug compliance due to the size of its dosage form.